Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
5 Great Youngster Care Administrations To Watch in 2024 - 2ONE returns to Red Sea with new service
- 3OpenAI launches ChatGPT Health to connect medical records, wellness apps
- 4Exploring the Main Year of Life as a parent: Individual Encounters
- 5RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- The Ascent of the Kona SUV: How Hyundai's Reduced Hybrid Is Vanquishing the Streets
- Wedding trip Objections in the US
- Step by step instructions to Prepare with Senior Protection for Inward feeling of harmony.
- Flourishing in a Remote Workplace: Individual Techniques
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
- Vote in favor of your Favored sort of footwear
- A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Netflix's Eddie Murphy documentary explains 'Saturday Night Live' beef: 'That's why I didn't go back for years'
